Stocks Health care ALXO
NASDAQ · Health careAlx Oncology Holdings Inc (ALXO)
It posted a net loss of $80.9M. In fiscal 2025 capital spending exceeded operating cash flow by $84.4M. At June 30, 2026 it held $22.7M in cash against $10.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Alx Oncology Holdings Inc
- Net worth
- Alx Oncology Holdings Inc has a market value (market cap) of $153.5M at the latest share price, and shareholders' equity of $136.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $0, with a net loss of $123.5M.
- Cash flow
- In fiscal 2025 operations used $84.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Alx Oncology Holdings Inc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Alx Oncology Holdings Inc does
Alx Oncology Holdings Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ALXO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$101.7M | -$1.90 | -$84.4M |
| 2024 | n/a | -$134.9M | -$2.58 | -$122.4M |
| 2023 | n/a | -$160.8M | -$3.74 | -$131.6M |
| 2022 | $0 | -$123.5M | -$3.03 | -$90.7M |
| 2021 | $0 | -$83.5M | -$2.07 | -$68.8M |
| 2020 | $1.2M | -$45.7M | -$2.76 | -$38.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Alx Oncology Holdings Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 16, 2026Activist stake changed SCHEDULE 13D/A
- October 15, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 30, 2026
- June 26, 2026
- June 11, 2026
- May 27, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Alx Oncology Holdings Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $5.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 17, 2026 | Wong ShellySVP, FINANCE AND CAO | Sold | 573 | $1.1K |
| August 17, 2026 | Lettmann JasonCHIEF EXECUTIVE OFFICER, Director | Sold | 2,230 | $4.3K |
| July 1, 2026 | Wong ShellySVP, FINANCE AND CAO | Sold | 1,404 | $2.9K |
| March 19, 2026 | Pinto ShellySVP, FINANCE AND CAO | Sold | 903 | $2K |
| March 19, 2026 | Lettmann JasonCHIEF EXECUTIVE OFFICER, Director | Sold | 12,311 | $26.7K |
| February 18, 2026 | Pinto ShellySVP, FINANCE AND CAO | Sold | 565 | $1.3K |
| February 17, 2026 | Lettmann JasonCHIEF EXECUTIVE OFFICER, Director | Shares withheld for tax | 2,201 | $5K |
| February 2, 2026 | Goodman Corey SDirector, 10% owner | Boughtindirect | 3,184,713 | $5M |
Who owns ALXO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Goodman Corey S13D, may seek influence with 6 related filers | 9.99% | October 16, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | February 9, 2026 |
| Redmile Group, LLC13G, passive with 2 related filers | 6.8% | May 15, 2026 |
| HBM Healthcare Investments (Cayman) Ltd.13G, passive | 6.5% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 94 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 13,011,849 | 0 |
| venBio Partners LLC | 12,884,638 | 0 |
| BlackRock, Inc. | 7,399,530 | +6,951,731 |
| Redmile Group, LLC | 7,392,504 | -571,684 |
| Blackstone Inc. | 6,593,543 | +766,999 |
| Driehaus Capital Management LLC | 6,025,240 | +290,620 |
| Silverarc Capital Management, LLC | 5,744,757 | new |
| TCG Crossover Management, LLC | 5,655,487 | -7,356,362 |
| Vanguard Capital Management LLC | 4,973,436 | +793,700 |
| Vivo Capital, LLC | 3,184,713 | 0 |
| Marshall Wace, Llp | 3,071,496 | -685,720 |
| 5AM Venture Management, LLC | 3,057,325 | 0 |
| Almitas Capital LLC | 2,938,431 | -235,403 |
| Orbimed Advisors LLC | 2,866,256 | 0 |
| Geode Capital Management, LLC | 2,787,809 | +2,294,372 |
| Two Sigma Investments, LP | 2,178,176 | +590,343 |
| Millennium Management LLC | 1,543,594 | -444,965 |
| Nantahala Capital Management, LLC | 1,500,000 | new |
| State Street Corp | 1,498,905 | +1,323,077 |
| Jpmorgan Chase & Co | 1,044,728 | +1,044,629 |
Insiders
3 insiders reported holding 8,835,245 shares in total, about $9.8M at the last price.
| Holder | Shares |
|---|---|
| Goodman Corey SDirector, 10% owner | 8,453,0388,453,038 held indirectly |
| Lettmann JasonCHIEF EXECUTIVE OFFICER, Director | 294,379 |
| Wong ShellySVP, FINANCE AND CAO | 87,828 |
Questions about ALXO
What does Alx Oncology Holdings Inc do?
Alx Oncology Holdings Inc is a company in the Health care sector, listed on NASDAQ as ALXO. Its shares trade on NASDAQ under the ticker ALXO.
What is Alx Oncology Holdings Inc's net worth?
Alx Oncology Holdings Inc has a market value (market cap) of $153.5M at the latest share price, and shareholders' equity of $136.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Alx Oncology Holdings Inc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $80.9M.
When did Alx Oncology Holdings Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from October 16, 2026.
When is Alx Oncology Holdings Inc's next earnings report?
Alx Oncology Holdings Inc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare ALXO with
Follow ALXO
Get an email when Alx Oncology Holdings Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Alx Oncology Holdings Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.